What Does Alphamab Oncology Do?

Total employees850
HeadquartersSuzhou
Founded2009

Alphamab Oncology (江苏康宁杰瑞生物制药有限公司, HKEX: 9966) is a clinical-stage biopharmaceutical company focusing on the research, development, manufacturing, and commercialization of innovative biologics for oncology. Headquartered in Suzhou, China, the company has built a globally competitive proprietary biologics platform in bispecific and multi-specific antibody technology. Its pipeline includes several drug candidates for various cancer indications, with some in late-stage clinical trials or already approved in China, such as Envafolimab (KN035), the world's first subcutaneously administered PD-L1 inhibitor. Alphamab Oncology is committed to addressing unmet medical needs and providing effective cancer treatments to patients worldwide.

Where Is Alphamab Oncology's Headquarters?

Alphamab Oncology officeAlphamab Oncology officeAlphamab Oncology officeAlphamab Oncology office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters serves as the core for Alphamab Oncology's R&D, manufacturing, corporate strategy, and administrative operations. It houses advanced laboratories and GMP-compliant production facilities.

Notable Features:

State-of-the-art research and development labs, integrated manufacturing facilities capable of producing clinical and commercial-grade biologics, and modern office spaces designed for collaboration and innovation.

Work Culture:

A science-driven, innovative, and collaborative work environment. Employees are often highly skilled researchers, scientists, and biopharmaceutical professionals dedicated to advancing cancer therapies. There's a strong emphasis on R&D and achieving breakthroughs.

HQ Significance:

The Suzhou headquarters is pivotal to Alphamab's strategy, leveraging the rich talent pool, supportive government policies, and robust infrastructure of the Suzhou BioBAY and the broader Yangtze River Delta biopharmaceutical ecosystem.

Values Reflected in HQ: The headquarters reflects Alphamab's commitment to innovation, quality, and scientific excellence through its advanced infrastructure and strategic location within a leading biotech cluster.

Location:

Alphamab Oncology, while headquartered and with primary operations in China, maintains a global outlook. Its functions supported globally include international clinical trials (e.g., in the US, Australia), strategic partnerships for co-development and commercialization in various regions (e.g., with Pfizer for certain territories), and engagement with international regulatory bodies. The company aims to bring its innovative oncology drugs to patients worldwide.

Street Address:

108 Xinghu Street, Suzhou BioBAY, Suzhou Industrial Park

City:

Suzhou

State/Province:

Jiangsu

Country:

China

Where Else Does Alphamab Oncology Operate Around the World?

Shanghai, China

Address: Specific address not publicly detailed, likely within a major business or research park.

Supports broader clinical trial management across China, facilitates partnerships, and engages with the financial community.

United States (Potentially virtual or representative office)

Address: Not publicly specified; operations may be managed through partners or CROs for clinical trials.

To advance its pipeline in the US market and support global drug development programs.

Buying Intent Signals for Alphamab Oncology

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Alphamab Oncology? Meet the Executive Team

As of April 2025, Alphamab Oncology' leadership includes:

Dr. Ting Xu (徐霆) - Founder, Chairman, and Chief Executive Officer
Dr. John Li (李景荣) - Chief Medical Officer
Mr. Wang Jin (王津) - Chief Financial Officer
Dr. Peng Liu (刘鹏) - Senior Vice President, Head of Process Development and Manufacturing
Dr. Xiu Cai (蔡秀) - Senior Vice President, Head of Clinical Development

Who's Investing in Alphamab Oncology?

Alphamab Oncology has been backed by several prominent investors over the years, including:

PAG (Advantech Capital)
Hillhouse Capital Group
China Reform Fund Management
Hudson Bay Capital Management
Lake Bleu Capital
OrbiMed Advisors
CICC Capital
Vivo Capital

What Leadership Changes Has Alphamab Oncology Seen Recently?

Hire1
Exits0

Alphamab Oncology has seen some key executive movements aimed at strengthening its clinical development and strategic leadership. Based on available information, there has been at least one notable hire.

New Appointments:

Dr. John Li (李景荣), Dr. John Li joined Alphamab Oncology as Chief Medical Officer to lead and expand the company's clinical development strategy and execution for its innovative oncology pipeline.

What Technology (Tech Stack) Is Used byAlphamab Oncology?

Discover the tools Alphamab Oncology uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Alphamab Oncology Email Formats and Examples

Alphamab Oncology likely uses common corporate email formats. Based on typical patterns for companies of its nature and region, formats often involve a combination of the employee's first name initial and last name, or full first name and last name.

[firstinitial][lastname]@alphamabonc.com or [firstname].[lastname]@alphamabonc.com

Format

txu@alphamabonc.com (example for Ting Xu if using [firstinitial][lastname])

Example

70%

Success rate

What's the Latest News About Alphamab Oncology?

Alphamab Oncology Press Release / HKEX Announcement2024-03-27

Alphamab Oncology Announces 2023 Annual Results Highlighting Pipeline Progress and Commercialization Efforts

Alphamab Oncology reported its annual financial results for 2023, detailing significant progress in its clinical pipeline, including advancements for key drug candidates like KN046 and KN026. The company also highlighted the commercial performance of Envafolimab (KN035) and its strategic focus on global expansion....more

Alphamab Oncology Press Release2024-02-05

Alphamab Oncology's Envafolimab (KN035) Receives NMPA Approval for a New Indication in Advanced Colorectal Cancer

The National Medical Products Administration (NMPA) of China approved Envafolimab (KN035) for the treatment of adult patients with previously treated microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer. This marks a significant milestone for the drug and patients....more

Alphamab Oncology Press Release2023-12-18

Alphamab Oncology's Bispecific Antibody KN026 Meets Primary Endpoint in Phase III Study for HER2-Positive Gastric Cancer

Alphamab Oncology announced that its independently developed HER2-bispecific antibody KN026 combined with chemotherapy met the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial as a first-line treatment for HER2-positive gastric or gastroesophageal junction cancer....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Alphamab Oncology, are just a search away.